T1185

Rofecoxib (MK 966) binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in an inhibition of the conversion of arachidonic acid to prostaglandins. Rofecoxib is a synthetic, nonsteroidal derivative of phenyl-furanone with anti-inflammatory, antipyretic and analgesic properties and potential antineoplastic properties. COX-related metabolic pathways may represent key regulators of cell proliferation and neo-angiogenesis. Some epithelial tumor cell types overexpress pro-angiogenic COX-2.

Lipopolysaccharides (LPS), derived from Escherichia coli O55:B5, are essential components of the outer membrane of Gram-negative bacteria. Composed of lipid A, a core oligosaccharide, and an O-specific polysaccharide, LPS exhibits strong immunogenicity. It activates immune cells via the TLR4 receptor, induces chemotactic cell migration and cytokine secretion, and helps maintain the integrity of the bacterial outer membrane, protecting against bile salts and lipid-based antibiotics. LPS is commonly used to establish inflammatory models, including arthritis, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), and gastrointestinal disease models.

Litronesib is a selective inhibitor of mitosis-specific kinesin Eg5. It also has antitumor activity.

LIN28 inhibitor LI71 is a potent and cell-permeable compound that effectively abolishes LIN28-mediated oligouridylation, with an IC50 of 7 µM (micromolar).

Lin28-let-7a antagonist 1, with an IC50 of 4.03 μM for Lin28A-let-7a-1 interaction,and shows a clear antagonistic effect against the Lin28-let-7a interaction.

Linaclotide, developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation, is a potent and selective guanylate cyclase C agonist.

Linezolid D3, a deuterium-labeled version of Linezolid, is a synthetic antibiotic designed to halt the initiation of bacterial protein synthesis.

Lipofermata, a fatty acid transport protein (FATP) inhibitor, prevents lipid transport to melanoma cells and reduces their growth and invasion.

LIT-001 free base improves social interaction in a mouse model of autism. LIT-001 free base is the first nonpeptide oxytocin receptor (OT-R) agonist (EC50=55 nM; Ki=226 nM).

LIT-001 improves social interaction in a mouse model of autism.It is the first nonpeptide oxytocin receptor agonist with EC50 of 55 nM and Ki of 226 nM.

Lith-O-Asp is a competitive, selective sialyltransferase inhibitor (ST3Gal Ki = 1.3 μM). It inhibits cancer cell adhesion and invasion by reducing surface sialylation in metastasis research.

CCT129254, an effective Akt inhibitor, reduces the motility of melanoma cells in vivo.